ResMed Inc. reported its Q4 2025 earnings, revealing a robust financial performance with revenue reaching $1.35 billion, surpassing the forecast of $1.33 billion. Despite this positive financial ...

ResMed (NYSE:RMD) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates ...

Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy. A strong earnings growth history and ...

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential ...

The S9 Elite™ is a whisper quiet, elegant and comfortable therapy system for the treatment of Obstructive Sleep Apnoea (OSA). The S9 Elite provides Continuous Positive Airway Pressure (CPAP) with Easy ...

For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business ...

ResMed plans to sign a lease for an about 446,500-square-foot building on Collins Road in Greenwood. The company is seeking a nearly $500,000 three-year tax break from the Greenwood City Council.

Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Resmed ...

ResMed CEO Mick Farrell on Thursday revealed the Trump administration will not apply tariffs to goods it makes in Australia or Singapore. “Our products are used to treat patients with chronic ...

Trump's universal 10% tariffs will impact healthcare names like Ansell and ResMed, while Cochlear, Ramsay and Sonic Healthcare face no direct exposure Ansell may need a 6-7% price hike to offset ...

ResMed Inc (ASX: RMD) shares are rising on Friday morning. At the time of writing, the sleep disorder treatment company's shares are up 0.5% to $40.70. This follows the release of the company's second ...